Lyell Immunopharma announced promising initial clinical and translational data from its Phase 1 trial of LYL797, a reprogrammed ROR1 CAR T-cell product for blood cancers. The trial showed dose-dependent antitumor activity in ROR1+ relapsed/refractory triple-negative breast cancer, with a 40% objective response rate and 60% clinical benefit rate at the highest dose. No significant safety issues were observed, and development is expanding into new tumor types. An IND submission for LYL119, a next-generation ROR1-targeted CAR T cell product, has been completed.